Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

Last week, while I was brushing my teeth before bed, my phone flashed up with a voice note sent by a close friend. "Rachel!" my friend yelled down the phone with some urgency. "The days of the dick ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

NEW YORK CITY – Curtis Sliwa says he’s charging into the final stretch of New York City’s mayoral race like "Braveheart" — confident, defiant and ready to die on his sword for the city he loves. In an ...